Ovagen 20mg

Ovagen 20 mg is a high-purity lyophilized peptide research compound supplied exclusively for scientific investigation and controlled laboratory experimentation. For research use only — not for human or veterinary use.  

Product Overview

Ovagen is a short-chain peptide research compound developed for advanced laboratory investigations involving peptide chemistry, molecular signalling and intracellular regulatory pathways. Its compact and defined molecular structure has attracted scientific interest within experimental peptide research, where investigators continue to explore short-chain peptide interactions, cellular communication and biochemical regulatory mechanisms under carefully controlled laboratory conditions. This preparation contains 20 mg of lyophilized Ovagen supplied in a sealed research vial. Independent analytical testing confirmed an assay content of 22.1 mg for this production batch. Chromatographic analysis confirmed greater than 99.8 percent purity, while identity was independently evaluated through FTIR spectrum analysis, retention time confirmation and molecular ion mass identification. Microbiological analysis reported a total aerobic microbial count of 2.5 × 10¹ CFU/g and a total yeast and mold count of 0 CFU/g, while bacterial endotoxin analysis returned a result of 0.005 EU/mg. Comprehensive elemental impurity screening additionally reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm. With its defined molecular identity and comprehensive third-party analytical documentation, Ovagen provides researchers with a batch-characterised peptide material suitable for controlled peptide investigations and in vitro laboratory studies.  

Peptide Overview

Ovagen is a short-chain peptide research compound commonly utilised in laboratory investigations involving peptide chemistry, molecular interactions and intracellular communication. Its compact molecular structure provides researchers with a defined experimental material suitable for controlled investigations involving peptide-mediated molecular interactions and biochemical signalling systems. Researchers employ Ovagen in experimental models designed to investigate peptide signalling pathways, molecular interactions and cellular regulatory mechanisms. Its defined molecular structure and analytical characteristics allow identity and quality parameters to be evaluated using complementary chromatographic, spectroscopic and mass spectrometric techniques. Today, Ovagen continues to form part of the expanding field of short-chain peptide research and controlled experimental peptide science.  

Historical Background and Scientific Context

Short-chain peptides have become increasingly important research materials within modern peptide chemistry because their compact molecular structures allow investigators to examine specific molecular interactions under highly controlled experimental conditions. Advances in peptide synthesis and analytical chemistry have significantly improved the ability to manufacture and independently characterise research compounds such as Ovagen. Modern analytical technologies including chromatographic analysis, FTIR identification and mass spectrometry allow researchers to evaluate peptide identity, assay content, purity and manufacturing consistency. These analytical techniques can be complemented by bacterial endotoxin testing, microbiological analysis and elemental impurity screening to provide comprehensive batch-specific analytical documentation. Today, Ovagen remains part of the growing field of investigational peptides utilised exclusively for scientific research and controlled in vitro experimentation.  

Mechanistic Focus in Research

Within controlled laboratory environments, Ovagen may be investigated in relation to short-chain peptide biology, molecular signalling and intracellular communication systems. Research investigations frequently explore:

• Short-chain peptide biology
• Peptide-mediated signalling pathways
• Intracellular molecular communication
• Cellular regulatory mechanisms
• Biochemical pathway analysis
• Molecular peptide interactions
• Comparative peptide investigations
• Controlled in vitro peptide studies

These experimental models allow researchers to investigate peptide-related molecular mechanisms while maintaining carefully controlled laboratory conditions.  

Analytical Verification (COA)

Each batch of Ovagen supplied by Grail Formula undergoes comprehensive independent third-party laboratory analysis to characterise peptide identity, assay content, purity, microbiological parameters and elemental impurities. Analytical testing for this batch was performed by Liquilabs s.r.o. Czechia using chromatographic, spectrometric, microbiological and mass spectrometry techniques. Batch: GF-OVAG20-B241

• Assay Content: 22.1 mg
• Purity: greater than 99.8 %
• Identification by FTIR Spectrum: 997
• Identification by Retention Time: 0.981
• Molecular Ion Mass Identification: 375 Da
• Bacterial Endotoxins: 0.005 EU/mg
• Total Aerobic Microbial Count: 2.5 × 10¹ CFU/g
• Total Yeast and Mold Count: 0 CFU/g

Independent peptide screening measured an assay content of 22.1 mg with a reported analytical uncertainty of ±0.1 mg. Purity analysis confirmed greater than 99.8 percent purity for the tested Ovagen research material. Identity was evaluated through FTIR spectrum analysis with a reported result of 997 and retention time analysis with a result of 0.981. Mass spectrometry identified a molecular ion mass of 375 Da with a reported analytical uncertainty of ±1 Da, providing an additional independent identity parameter for the tested material. Bacterial endotoxin testing returned a result of 0.005 EU/mg. Microbiological testing reported a total aerobic microbial count of 2.5 × 10¹ CFU/g with a reported uncertainty of ±1 and a total yeast and mold count of 0 CFU/g. Independent elemental impurity analysis reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm. These analytical procedures provide transparent batch-specific documentation of peptide identity, assay content, purity, microbiological results, endotoxin levels and elemental impurity characteristics for the tested Ovagen research material.  

Research Applications

Within controlled laboratory environments, Ovagen may be utilised in experimental models designed to investigate peptide biology, intracellular signalling pathways and molecular regulatory mechanisms. Examples of research applications include:

• Short-chain peptide investigations
• Peptide signalling research
• Intracellular signalling investigations
• Molecular pathway analysis
• Biochemical regulation studies
• Comparative peptide investigations
• Molecular interaction research
• Controlled in vitro peptide studies

These applications are intended exclusively for scientific and laboratory investigation.  

Grail Formula Quality

Every Grail Formula research compound is supported by comprehensive independent analytical verification and transparent batch-specific laboratory documentation. For this production batch, independent laboratory testing included:

• Peptide identity confirmation
• Assay content determination
• Purity assessment
• Molecular ion mass identification
• Retention time confirmation
• FTIR spectrum identification
• Bacterial endotoxin analysis
• Microbiological analysis
• Elemental impurity screening
• Complete batch-specific traceability

Independent laboratory analysis provides researchers with detailed analytical information relating directly to the tested production batch rather than relying solely on general product specifications. This approach supports analytical transparency and complete batch-specific traceability.  

When You Choose Grail Formula

When selecting Grail Formula, researchers receive independently analysed research compounds supported by detailed Certificates of Analysis and transparent batch-specific laboratory documentation. For Ovagen 20 mg batch GF-OVAG20-B241, independent analysis was performed by Liquilabs s.r.o. Czechia and the Certificate of Analysis was published on 20 September 2026. The analytical programme included assay determination, purity assessment, FTIR spectrum identification, retention time verification, molecular ion mass identification, bacterial endotoxin testing, microbiological analysis and comprehensive elemental impurity screening. This multi-method analytical approach provides researchers with extensive independent information regarding the analytical characteristics of the tested Ovagen research preparation.  

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

• Independently analysed by Liquilabs s.r.o. Czechia
• Greater than 99.8 % purity confirmed by COA
• Assay content verified at 22.1 mg
• Identification confirmed by FTIR spectrum and retention time analysis
• Molecular ion mass identified at 375 Da
• Bacterial endotoxin level of 0.005 EU/mg
• Total aerobic microbial count: 2.5 × 10¹ CFU/g
• Total yeast and mold count: 0 CFU/g
• All reported elemental impurities below 0.001 ppm
• Complete batch-specific COA traceability
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.